Genitourinary Malignancies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 August 2024 | Viewed by 165
Special Issue Editor
Interests: chemotherapy; medical oncology; renal cell carcinoma; prostate cancer; transitional cell carcinoma; germ cell tumors; hepatocellular carcinoma
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Genitourinary malignancies, including prostate, bladder, kidney, and testicular cancers, are at the forefront of innovation, with a continuous influx of novel therapeutics reshaping treatment paradigms. Although the pipeline of new therapeutics continues to evolve, achieving the ultimate goal of personalized medicine proves challenging. The scarcity of reliable biomarkers predicting responses or toxicities to cancer treatments has prompted the development of several drug combinations which ultimately improve outcomes. Nevertheless, the introduction of these combinations, coupled with numerous recent changes in frontline treatments, has intensified the complexity of treatment selection and sequencing, as well as the optimization of toxicity management and quality of life.
This Special Issue welcomes manuscripts addressing the unknowns surrounding treatment optimization, the development of predictive markers, the refinement of therapy sequencing, and the strategies to improve and prevent drug toxicity as well as patients’ quality of life.
Dr. Dominick Bosse
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- genitourinary malignancy
- renal cell carcinoma
- prostate cancer
- urothelial cancer
- germ cell tumor
- outcomes
- toxicities
- quality of life
- markers
- treatment sequencing
